Imiquimod 3.75% (Zyclara®)

Assessment Status Rapid Review Complete
Drug Imiquimod 3.75%
Brand Zyclara®
Indication For topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
Assessment Process
Rapid review commissioned 10/09/2013
Rapid review completed 18/09/2013
Rapid review outcome Full Pharmacoeconomic Assessment Not Recommended